Reverse vaccinology-based multi-epitope vaccine design against Indian group A rotavirus targeting VP7, VP4, and VP6...

Area of Science:

• Virology
• Immunology
• Vaccine Development

Background:

• Rotavirus A (RVA) causes severe gastroenteritis in children globally, especially in low-income countries.
• Current vaccines have limited efficacy and potential side effects like intussusception due to RVA's genetic diversity.
• The prevalent Indian RVA strain is G1P[8].

Purpose of the Study:

• To design and computationally evaluate a novel multiepitope vaccine against the prevalent Indian RVA strain.
• To identify conserved RVA epitopes for vaccine development.
• To assess the vaccine's potential immunogenicity and safety through in silico methods.

Main Methods:

• Phylogenetic analysis of Indian RVA molecular data.
• Identification and selection of conserved VP7, VP4, and VP6 capsid protein epitopes based on antigenicity, non-allergenicity, non-toxicity, and stability.
• In silico vaccine design, including epitope linkage, adjuvant incorporation, docking, normal mode analysis, and immune simulation.

Main Results:

• G1P[8] identified as the predominant RVA strain in India.
• Twenty stable, non-allergenic, and non-toxic epitopes were selected.
• The in silico designed vaccine demonstrated structural stability and favorable interactions with host immune receptors (integrins and TLRs).
• Immune simulations predicted the vaccine's ability to induce both humoral and cell-mediated immune responses.

Conclusions:

• The designed RVA multiepitope vaccine is a promising immunogen with potential efficacy against rotavirus infection.
• Computational findings support further development of this vaccine candidate.
• This approach may overcome limitations of existing RVA vaccines.